Systemic mycoses: a potential alert for complications in COVID-19 patients

G Segrelles-Calvo, GR de S Araujo… - Future Microbiology, 2020 - Taylor & Francis
As the global COVID-19 pandemic spreads worldwide, new challenges arise in the clinical
landscape. The need for reliable diagnostic methods, treatments and vaccines for COVID-19 …

A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase

S Khan, F Attar, SH Bloukh, M Sharifi, F Nabi… - International Journal of …, 2021 - Elsevier
The outbreaks of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in 2019,
have highlighted the concerns about the lack of potential vaccines or antivirals approved for …

[HTML][HTML] Tocilizumab, remdesivir, favipiravir, and dexamethasone repurposed for COVID-19: a comprehensive clinical and pharmacovigilant reassessment

MT Kelleni - SN Comprehensive Clinical Medicine, 2021 - Springer
In this manuscript, we discuss the expectations versus the real-world results of four
repurposed COVID-19 drugs: tocilizumab, remdesivir, favipiravir, and dexamethasone from …

[HTML][HTML] Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 …

FA Cadegiani, A Goren, CG Wambier… - New microbes and new …, 2021 - Elsevier
In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide,
ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 …

[HTML][HTML] Mucormycosis and COVID-19 an epidemic in a pandemic?

I Banerjee, J Robinson, M Asim, B Sathian… - Nepal journal of …, 2021 - ncbi.nlm.nih.gov
Mucormycosis and aspergillosis are rare, invasive and life-threatening infections primarily
caused by Rhizopus arrhizus and Aspergillus fumigatus with higher case fatality rates (> …

Exploration of luteolin as potential anti-COVID-19 Agent: Molecular docking, molecular dynamic simulation, ADMET and DFT Analysis

WA Ansari, T Ahamad, MA Khan… - Letters in Drug …, 2022 - ingentaconnect.com
Background: Coronavirus disease-2019 (COVID-19) has recently emerged as a pandemic
respiratory disease with mild to severe pneumonia symptoms. No clinical antiviral agent is …

COVID-19 and Ivermectin: Potential threats associated with human use

T Zaheer, K Pal, RZ Abbas, MPR Torres - Journal of Molecular Structure, 2021 - Elsevier
Drugs re-purposing due to COVID-19 virus has declared a number of useful candidates for
treatment and prevention of the virus. Ivermectin (IVM) has gained much popularity due to a …

[HTML][HTML] An In-silico investigation of potential natural polyphenols for the targeting of COVID main protease inhibitor

NH Aljarba, MS Hasnain, MM Bin-Meferij… - Journal of King Saud …, 2022 - Elsevier
The deadliest recent pandemic outbreak of COVID-19 disease has severely damaged the
socio-economic health of the people globally. Due to unavailability of any effective vaccine …

COVID‐19‐associated acute invasive fungal sinusitis: Clinical and imaging findings

AH Elmokadem, D Bayoumi, M Mansour… - Journal of …, 2022 - Wiley Online Library
Abstract Background and Purpose The purpose is to provide a comprehensive report
describing the clinical and imaging features of Coronavirus disease 2019 (COVID‐19) …

Outcomes of Ivermectin in the treatment of covid-19: a systematic review and meta-analysis

A Castañeda-Sabogal, D Chambergo-Michilot… - medRxiv, 2021 - medrxiv.org
Background To assess the outcomes of ivermectin in ambulatory and hospitalized patients
with COVID-19. Methods Five databases and websites for preprints were searched until …